Debt-laden Valeant Sells Its Assets, More Divestments Likely
Executive Summary
Troubled Valeant has started the new year by announcing the sale of some $2.1bn in assets to get funds to hone down its operations and to start easing its debt burden amid allegations of unethical practices.
You may also be interested in...
Bausch Health Boosts Ad Spending For Expanding OTC Eye Care Lineup
"We're investing more to drive growth as we allocate capital to support the launches of new products in the segment like Lumify, for DTC advertising that continue to drive sales growth of other US consumer products like our eye vitamins," says CEO Joseph Papa.
Bausch Health Boosts Ad Spending For Expanding OTC Eye Care Lineup
"We're investing more to drive growth as we allocate capital to support the launches of new products in the segment like Lumify, for DTC advertising that continue to drive sales growth of other US consumer products like our eye vitamins," says CEO Joseph Papa.
Bausch Health Boosts Ad Spending For Expanding Supplement Lineup
Canadian firm, recently renamed from Valeant Pharmaceuticals International, includes launches of Ocuvite Blue Light and PreserVision AREDS 2 Formula Chewable vitamins among its reasons for increasing its consumer health advertising spending. Q2 revenues for its consumer health segment were up 5% organically to $369m.